ETUDES (CLINIQUE DU SEIN)

ETUDES (CLINIQUE DU SEIN)
Service d'Oncologie - Radiothérapie
Octobre 2010
SEIN-NEO ADJUVANT
SEIN ADJUVANT
Ce
MAP QUANT : Mesure du grade génomique par MapQuant Dx : faisabilité en routine clinique et impact sur la
décision thérapeutique dans le cancer du sein en stade précoce
Date d’ouverture : Mars 2010
Ce
Aging - B32220096117: Elderly biomarker study Gene polymorphisms and gene products as biological markers of
aging and correlation with clinical geriatric assessment, tolerance of chemotherapy and outcome in elderly breast cancer
patients (“Biology of aging and chemotherapy tolerance”)
M
EORTC 10031 (SOFT) : Phase III évaluant le rôle de la suppression de la fonction ovarienne et le rôle de
l’Exemestane comme traitements adjuvants chez des patientes pré-ménopausées ayant un cancer du sein hormono-sensible
Date d’ouverture : Juin 2004
G
MINDACT : A prospective, randomised study comparing the 70-gene expression signature with common clinicalpathological criteria in selecting patients for adjuvant chemotherapy in patient with ≤ N1 breast cancer.
Date d’ouverture : mars 2007
Ce
O-HERA : Etude observationnelle des évènements cardiaques chez des patients présentant un cancer du sein
HER2 + au stade précoce traité par Herceptine.
Date d’ouverture : Septembre 2007
M
SNP Radiothérapie GAND : modèle prédictif pour les effets secondaires au niveau de la peau à la suite d’une
radiothérapie.
Date d'ouverture: Mars 2010
D-Care : Amgen 20060359 : A randomized, double-blind, placebo-controlled, multi-center phase 3 study of
Denosumab as adjuvant treatment for women with early stage breast cancer at high risk of recurrence.
Date d'ouverture: Octobre 2010
C
C
SOLD : phase III study comparing trastuzumab plus docetaxel followed by FEC to the same regimen followed by
single-agent trastuzumab as adjuvant treatments for early breast cancer.
Date d'ouverture: Mai 2010
Ce
CYP-TAMBRUT 2: An observational study to assess response to tamoxifen with measurable but inoperable or
metastatic ER-positive breast cancer by the the ‘tamoxifen activity score’ based on drug interaction and polymorphisms in
gens coding for tamoxifen metabolising enzymes.
Date d'ouverture: Mai 2010
Ce
CYP-TAMBRUT-3 : Prevalence of genetic polymorphisms in genes coding for tamoxifen metabolising enzymes, in
postmenopausal ER-positive breast cancer patients according to uterine and biochemical changes and tolerability of
tamoxifen.
Date d'ouverture: Mai 2010
Ce
SOLE : Cont letrozole vs intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for
postmenop women with hormone-receptor +, node positive early stage BC
Date d'ouverture: Octobre 2010
CMSE Oncologie Clinique du sein (octobre 2010).doc
SEIN METASTASE
C
TRIO-CIRG 012 : IMC-1121B + Docetaxel vs placebo + docetaxel in previously untreated patients with unresectable
locally advanced or MBC HER neg
Fermeture temporaire des inclusions
Date d’ouverture : 17 juin 09
C
COMPLETE (EGF108919) : Comparison of Lapatinib Efficacy vs Trastuzumab, each with a taxane , 1° line in MBC
Date d’ouverture : septembre 2008
Ce
BOLERO-3 : Herceptine and Vinorelbine +/- Everolimus in 2
to trastuzumab
Date d'ouverture : janvier 2010
nd
or 3rd line MBC pre-treated with a taxane and resistant
Ce
PHEREXA : PAREXEL : 2° line Herc + Xeloda +/- pertuzumab in MBC HER2+ that have progressed after one line
trastuzumab-based therapy in the metastating setting
Date d'ouverture : 10 février 2010
Ce
THYME: AZD8931 in combination with paclitaxel in patients with advanced solid tumours and in selected population
with low HER2-expressing.
Date d'ouverture : septembre 2010
ETUDES EN PROJET
C
NEO-BIG 01-09 (SEIN) : Luminal B trial.
C
WT1-AS15-BRS-001 : a double blind, placebo-controlled phase I/II sudy of neoadjuvant and adjuvant treatment with WT1-A10 +
AS15 antigen specific cancer immunotherapeutic in combination with standard therapy in women with WT1-positive stage II or III breast
cancer
C
EORTC 10054 (Lapatax) : Trial phase I-II study of Lapatinib and Docetaxel as neoajuvant treatment for HER-2 positive locally
advanced/inflammatory or large operable breast cancer
C
EORTC 10093 : Pilot study of secondary adjuvant treatment with Trastuzumab for elimination of hER2 positive Circulating Tumor
cells in women with HER2 neg early breast cancer.
M
ANABEL: A muticenter , post authorization study to observe in daily clinical practice the progression of free-survival in patients who
receive AVASTIN in 1st line MBC in Belgium
C
EGF114299 : Safety and efficacy of lapatinib + trastuzumab + aromatase inhibitor (AI) vs trastuzumab + an AI vs lapatinib + AI
as 1stline in postmenop with hormone receptor +, HER2+ MBC who have received trastuzumab and endocrine therapy in neoadjuvant and/or
adjuvant setting.
2